ClinicalTrials.gg
RecruitingNCT07105215Updated Nov 26, 2025

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

A Phase 1/2 interventional study of RC278 in Solid Tumors, sponsored by RemeGen Co., Ltd.. Recruiting at 39 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by RemeGen Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
312
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC278 at the RP2D dose;

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this study, sign the form, and be able to adhere to the study protocol;
  2. Age between 18 and 75 years (including 18 and 75 years);
  3. PS score of 0 or 1;
  4. Expected survival ≥12 weeks;
  5. According to v1.1 criteria, based on imaging examinations, there is at least one measurable target lesion;
  6. Sufficient bone marrow, liver, kidney, and blood clotting function

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, breastfeeding, or intending to become pregnant subjects.
  2. Subjects with .
  3. Subjects with unresolved toxicities from prior anti-tumor therapy not recovered to v5.0 Grade 1.
  4. Subjects with known or delayed allergic reactions to any component of the drug or similar drugs.
  5. Subjects with acute, chronic, or symptomatic infections.
  6. Subjects with uncontrolled cardiovascular diseases.
  7. Subjects with confirmed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severely impaired pulmonary function, or other pulmonary diseases.
  8. Subjects with a history of cirrhosis ( B or C class).
  9. Subjects with active inflammatory bowel disease.
  10. Subjects with uncontrolled diabetes ( ≥ 10%).
  11. Subjects who experienced arterial/venous thromboembolic events, deep vein thrombosis, pulmonary embolism, or stroke within 6 months prior to the first dose.
  12. Subjects with pericardial effusion or cardiac tamponade, or third-space fluid accumulation, which, in the investigator's judgment, cannot be controlled or stabilized by drainage or other methods.
  13. Subjects with active diseases requiring systemic treatment within the past 2 years.
  14. Subjects with a history of other invasive within 5 years prior to the first dose, or evidence of residual disease from a previously diagnosed malignancy.
  15. Subjects with a history of other acquired or congenital immunodeficiency diseases or organ transplantation.
  16. Subjects with a history or current diagnosis of uncontrolled psychiatric disorders.
  17. Subjects with poor adherence, who are unlikely to comply with the trial procedures.
  18. Subjects with any other diseases, metabolic abnormalities, physical examination abnormalities, or laboratory abnormalities, which, in the investigator's judgment, raise suspicion of an underlying condition making the subject unsuitable for the investigational drug, or which may affect the interpretation of the study results, or place the subject at high risk.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    RC278 (Phase I, dose escalation)

    There are five escalating dose cohorts.

    Drug: RC278

  • Experimental
    RC278 (Phase I, dose expansion)

    The recommended dose from the dose-escalation stage and other potential doses will be further explored.

    Drug: RC278

  • Experimental
    RC278 (Phase I, dose optimization)

    Based on the safety, pharmacokinetic (PK), and efficacy data from the subjects, select at least two dose levels and randomly assign subjects in a 1:1 ratio to determine the recommended Phase II dose (RP2D) for entering the Phase II stage.

    Drug: RC278

  • Experimental
    RC278 (Phase II)

    In the multi-indication cohort expansion phase, further assess the efficacy and safety of RC278 in various cancer types using the RP2D.

    Drug: RC278

Interventions

  • DrugRC278

    Intravenous (IV) administration of RC278 Q3W. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.

    Also known as: RC278 For Injection

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT)

    DLT is defined as the adverse events (AEs) occurring during the DLT observation period that the investigator determines to be related to the RC278 treatment.

    Time frame: 24 months

  2. Incidence and severity of adverse events/serious adverse events (graded according to NCI CTCAE v5.0)

    AE assessed by investigator exclusively related to subject's underlying disease or medical condition \[graded according to the CTCAE Version 5.0\].

    Time frame: 24 months

  3. Determine RP2D of RC278

    To determine the RP2D for further evaluation of RC278 in subjects with advanced solid tumor.

    Time frame: 24 months

  4. MTD and/or MAD

    To determine the MTD and/or MAD for further evaluation of RC278 in subjects with advanced solid tumor.

    Time frame: 24 months

  5. Investigator assessed ORR according to RECIST v1.1 criteria

    Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline. ORR is evaluated by the number of participants with best overall response of CR and PR (Confirmed CR/PR assessment require at least 1 repeat).

    Time frame: 24 months

07

Study locations

39 of 39 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Aug 5, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
May 31, 2030
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07105215
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Aug 11, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Nov 26, 2025

Study contacts

Xiaohong Su
Contact
na.su@remegen.com
+8610-65018841

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion